课题基金 / 基金详情

STUDY OF SELECTED LATE EFFECTS IN PATIENTS TREATED FOR NONHODGKINS LYMPHOMA

STUDY OF SELECTED LATE EFFECTS IN PATIENTS TREATED FOR NONHODGKINS LYMPHOMA
对接受非霍奇金淋巴瘤治疗的患者的选定迟发效应的研究
批准号:
6246639
负责人:
JULIE BLATT
金额:
$1.91万
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-12-01 至 1997-11-30

项目摘要

项目成果

JULIE BLATT的其他基金

相关文献

中文摘要
翻译
我们假设儿童期接受非霍奇金淋巴瘤治疗的患者 淋巴瘤可能会增加心脏,性腺或肺 毒性和第二恶性肿瘤的发生率较高,如果他们有 某些化疗的高累积剂量。 的识别 毒性较小但疗效相同的化疗方案可 帮助我们设计毒性更小的研究。 患者将接受治疗 对这些不同器官系统的直接评估。 这项研究是CCG- 广泛,并基于随机接受 分配的治疗方案。
英文摘要
We hypothesize that patients treated during childhood with non-Hodgkin's lymphoma may have an increased incidence of cardiac, gonadal or pulmonary toxicity and a higher incidence of second malignancies if they have had high cumulative doses of certain chemotherapies. The identification of chemotherapy regimens which have lesser toxicity with equal efficacy may help us to design less toxic studies. Patients will be undergoing therapy directed evaluations of these various organ systems. This study is CCG- wide and based on a population of patients who were treated with randomly assigned treatment regimens.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PEDIATRIC PHASE I TRIAL AND PHARMACOKINETIC STUDY OF LGC1057
PHASE I STUDY OF TOPOTECAN AND CISPLATIN IN THE TREATMENT OF SOLID TUMORS
THERAPEUTIC ROLE OF FERRITIN IN NEUROBLASTOMA
THERAPEUTIC ROLE OF FERRITIN IN NEUROBLASTOMA